DA Davidson raised the firm’s price target on Usana to $56 from $52.50 but keeps a Neutral rating on the shares. The company’s Q1 results saw sales and earnings upside but also benefited from $13M of sales pull-forward ahead of price increases, and $12M of elevated buying in China of immunity-boosting products in January, which fell back to normal in February, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on USNA: